Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Hldgs is expected to continue seeing growth in their revenue streams from both research and service sales, reaching $2,100 in the latest quarter. With a strong focus on meeting the needs of patients in the oncology market, coupled with the potential acquisition by Garda Therapeutics for $21.80 per share, the company faces minimal risks in its growth and potential legal risks as well.

Bears say

Assertio Hldgs is facing challenges due to its reliance on legacy products with limited market exclusivity and divestment of these assets for a low multiple of its one-year sales, leading to a decreased revenue stream. The term sheet for the acquisition of Assertio by Garda includes a "window-shop" period, which may lead to a higher offer from other potential buyers, but given the limited upside potential for Assertio's products, it is unlikely that a higher offer will emerge. Risks to the price target include potential delays or termination of the transaction, but the undisclosed contingent value right (CVR) is not expected to have a significant impact on the consideration for Assertio shareholders.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.